What is it about?
It investigates the expression of BORIS (an antigen normally expressed only in prostate and absent in females) as a potential tumor marker in breast cancer. Interestingly it is over-expressed in one of the peripheral blood leukocytes namely neutrophils. This is an easily obtained sample. Also we used Flow Cytometry which allows detection of the antigen specifically in the target cells
Featured Image
Why is it important?
The previous studies reported high expression of BORIS in the neutrophils of cancer breast patients. However the discrimination between benign and malignant lesions, which is the definition of a tumor marker, was not addressed.
Perspectives
Though BORIS could not discriminate between benign and malignant breast lesions, it still can be used as a therapeutic target in cases proved to be malignant
Professor Azza M Kamel
NCI, Cairo University
Read the Original
This page is a summary of: Increased expression of brother of the regulator of imprinted sites in peripheral blood neutrophils is associated with both benign and malignant breast lesions, Cytometry Part B Clinical Cytometry, May 2016, Wiley,
DOI: 10.1002/cyto.b.21378.
You can read the full text:
Contributors
The following have contributed to this page
